Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.
Adult
Betacoronavirus
COVID-19
Chemoprevention
Colchicine
/ therapeutic use
Coronavirus Infections
/ prevention & control
Female
Humans
Hydroxychloroquine
/ therapeutic use
Israel
Male
Middle Aged
Pandemics
/ prevention & control
Pneumonia, Viral
/ prevention & control
Retrospective Studies
SARS-CoV-2
Treatment Failure
Autoimmunity
COVID-19
Colchicine
Hydroxychloroquine
Rheumatic disease
SARS-CoV-2
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
28
04
2020
accepted:
29
04
2020
pubmed:
8
5
2020
medline:
11
6
2020
entrez:
8
5
2020
Statut:
ppublish
Résumé
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy. An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
Sections du résumé
BACKGROUND
BACKGROUND
Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear.
METHODS
METHODS
This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy.
RESULTS
RESULTS
An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively).
CONCLUSION
CONCLUSIONS
These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
Identifiants
pubmed: 32380315
pii: S1568-9972(20)30128-2
doi: 10.1016/j.autrev.2020.102566
pmc: PMC7198406
pii:
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Colchicine
SML2Y3J35T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102566Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
Isr Med Assoc J. 2020 Apr;22(4):211-213
pubmed: 32286020
JAMA. 2020 Mar 17;:
pubmed: 32181795
BMJ. 2020 Apr 14;369:m1483
pubmed: 32291262
Isr Med Assoc J. 2020 Apr;22(4):214-215
pubmed: 32286021
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
Lancet Infect Dis. 2006 Feb;6(2):67-9
pubmed: 16439323
Curr Pharm Des. 2018;24(6):684-689
pubmed: 29336252
BMC Infect Dis. 2017 Aug 25;17(1):589
pubmed: 28841914
Semin Arthritis Rheum. 2015 Dec;45(3):341-50
pubmed: 26228647
N Engl J Med. 2020 Apr 30;382(18):e67
pubmed: 32348666
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Trends Mol Med. 2020 May;26(5):483-495
pubmed: 32359479
Intern Med J. 2012 Sep;42(9):968-78
pubmed: 22827853
Lancet. 2020 Apr 11;395(10231):1168
pubmed: 32278370
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
JAMA. 2020 Feb 24;:
pubmed: 32091533
Rheumatol Int. 2019 Mar;39(3):517-523
pubmed: 30604205
Isr Med Assoc J. 2020 Apr;22(4):203-210
pubmed: 32286019
Arthritis Res Ther. 2009;11(4):R109
pubmed: 19604357
Clin Immunol. 2020 Apr 18;215:108426
pubmed: 32311462
Hellenic J Cardiol. 2020 Apr 3;:
pubmed: 32251729
Autoimmun Rev. 2020 Jun;19(6):102538
pubmed: 32268212
JAMA. 2020 Apr 13;:
pubmed: 32282022